2 Genentech execs jump to smaller biotechs—Chutes & Ladders by Conor Hale Friday, March 22, 2019 NGM Bio gains a Genentech/Lilly vet as R&D chief; Forma nabs a Genentech commercial exec as CEO; and Nimbus builds out its biology and preclinical teams.
Forma nabs long-time Genentech commercial executive as CEO by Conor Hale Thursday, March 21, 2019 Forma Therapeutics has poached a Genentech senior VP, Frank Lee, to be its new CEO, effective March 27.
As Merck boosts R&D pact, NGM Bio gains new R&D chief by Ben Adams Wednesday, March 20, 2019 It’s a pretty good news day for NGM Bio: Merck doubled down on its R&D pact, and it’s nabbed a Genentech executive to help run its trials.
Genentech pays Xencor $120M for rights to IL-15 cancer pipeline by Nick Paul Taylor Wednesday, February 6, 2019 The upfront sets the Roche subsidiary up to incorporate the candidates into its immuno-oncology combination strategy.
GSK chairman bows out—Chutes & Ladders by Conor Hale Friday, January 25, 2019 GSK chairman bows out; Editas CEO signs off; Roche dispatches exec to take over Genentech; and Vertex fires COO for code of conduct violation.
Erasca picks up $42M to target biological drivers of cancer by Amirah Al Idrus Tuesday, December 18, 2018 Though Erasca raised $40 million to bankroll its work to “not just treat, but actually cure cancer," it's keeping mum on the specifics.
Inflazome brings on new CMO after €40M VC round by Conor Hale Thursday, November 29, 2018 Inflazome has brought on Thomas Jung, M.D., Ph.D., to be its new chief medical officer and lead clinical development of its NLRP3 inhibitors.
Roche unveils TRK assay, as FDA clears Bayer-Loxo pantumor drug by Conor Hale Wednesday, November 28, 2018 Roche launched an in vitro diagnostic to detect tropomyosin receptor kinase proteins in cancer, with potential use in a range of solid tumor types.
Genentech snaps up NASH-focused Jecure Therapeutics by Amirah Al Idrus Wednesday, November 28, 2018 Genentech acquired Jecure Therapeutics and its stable of NLRP3 inhibitors for an undisclosed amount.
Genentech’s inhaled JAK1 inhibitor shows promise in asthma by Angus Liu Wednesday, November 21, 2018 Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.
